At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
AZD6422 CLDN18.2 CAR-T productbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
FTiH, Phase 1 Investigator-Initiated Trial (IIT) to Evaluate the Safety, Feasibility, Cellular Kinetics, and Preliminary Antitumor Activity of AZD6422 in Adult Participants With Advanced or Metastatic CLDN18.2+ GI Tumors
In Brief
A Phase 1 clinical trial evaluating AZD6422 CLDN18.2 CAR-T product for Gastrointestinal Tumors. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Tumors
CountriesChina
CollaboratorsAstraZeneca
Timeline
Phase 1CompletedFinished
202420252026
First PostedAug 2023
Enrollment StartDec 2023
Primary CompletionJun 2025
TodayJul 2026
First PostedAug 8, 2023
Enrollment StartDec 14, 2023
Primary CompletionJun 25, 2025
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2.9 years ago
Interventions
AZD6422 CLDN18.2 CAR-T productbiological
AZD6422 CAR-T product infusion after pre-conditioning